Shield Therapeutics (GB:STX) has released an update.
Shield Therapeutics plc successfully held its 2024 Annual General Meeting, with all proposed resolutions receiving overwhelming approval from its shareholders. The company highlighted its flagship product, Accrufer®/Feraccru®, an FDA-approved oral iron treatment for iron deficiency, which is a significant unmet medical need affecting millions. Shield Therapeutics’ growth is bolstered by strategic commercial agreements across the US, UK, EU, China, and other regions, ensuring the product’s global reach well into the 2030s.
For further insights into GB:STX stock, check out TipRanks’ Stock Analysis page.
